Edit Drescher

2.1k total citations · 3 hit papers
35 papers, 1.3k citations indexed

About

Edit Drescher is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Edit Drescher has authored 35 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 10 papers in Hematology and 10 papers in Immunology. Recurrent topics in Edit Drescher's work include Rheumatoid Arthritis Research and Therapies (22 papers), Autoimmune and Inflammatory Disorders Research (10 papers) and Spondyloarthritis Studies and Treatments (7 papers). Edit Drescher is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (22 papers), Autoimmune and Inflammatory Disorders Research (10 papers) and Spondyloarthritis Studies and Treatments (7 papers). Edit Drescher collaborates with scholars based in United States, Hungary and United Kingdom. Edit Drescher's co-authors include Désirée van der Heijde, Terence Rooney, Scott D. Beattie, Douglas Schlichting, Paul Emery, Maria Greenwald, Thijs Hendrikx, Dona Fleishaker, James Cheng‐Chung Wei and Sujatha Menon and has published in prestigious journals such as New England Journal of Medicine, Annals of the Rheumatic Diseases and Archives of Disease in Childhood.

In The Last Decade

Edit Drescher

34 papers receiving 1.3k citations

Hit Papers

Baricitinib in patients with inadequate response or intol... 2016 2026 2019 2022 2016 2017 2023 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
    2016 301 citations Maxime Dougados, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  2. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
    2017 272 citations Désirée van der Heijde, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →
  3. A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
    2023 74 citations Jay Tuttle, Edit Drescher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edit Drescher United States 13 922 486 463 301 211 35 1.3k
Šárka Forejtová Czechia 15 1.0k 1.1× 401 0.8× 403 0.9× 213 0.7× 195 0.9× 32 1.4k
Joel Kremer United States 7 1.1k 1.2× 464 1.0× 534 1.2× 214 0.7× 306 1.5× 12 1.5k
David Musselman United States 9 878 1.0× 339 0.7× 307 0.7× 174 0.6× 201 1.0× 16 1.3k
Charles Ludivico United States 9 741 0.8× 268 0.6× 352 0.8× 167 0.6× 228 1.1× 13 1.0k
Yvonne Sherrer United States 7 921 1.0× 441 0.9× 391 0.8× 116 0.4× 218 1.0× 11 1.3k
M. C. Genovese United States 10 634 0.7× 228 0.5× 320 0.7× 137 0.5× 162 0.8× 38 842
J. Box United States 7 763 0.8× 367 0.8× 356 0.8× 101 0.3× 217 1.0× 10 1.1k
Eva Pérez‐Pampín Spain 20 665 0.7× 331 0.7× 173 0.4× 126 0.4× 162 0.8× 62 1.1k
Alvina D. Chu United States 18 842 0.9× 728 1.5× 272 0.6× 188 0.6× 422 2.0× 34 2.2k
Artur Racewicz Poland 9 933 1.0× 660 1.4× 304 0.7× 171 0.6× 344 1.6× 14 1.5k

Countries citing papers authored by Edit Drescher

Since Specialization
Citations

This map shows the geographic impact of Edit Drescher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edit Drescher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edit Drescher more than expected).

Fields of papers citing papers by Edit Drescher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edit Drescher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edit Drescher. The network helps show where Edit Drescher may publish in the future.

Co-authorship network of co-authors of Edit Drescher

This figure shows the co-authorship network connecting the top 25 collaborators of Edit Drescher. A scholar is included among the top collaborators of Edit Drescher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edit Drescher. Edit Drescher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spiera, Robert, Valérie Devauchelle‐Pensec, Claire Owen, et al.. (2025). Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis & Rheumatology. 77(8). 1041–1051. 2 indexed citations
2.
Taylor, Peter C., Philip J. Mease, Kurt de Vlam, et al.. (2025). Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Annals of the Rheumatic Diseases. 84(6). 979–991. 2 indexed citations
3.
Buttgereit, Frank, Atul Singhal, Alan Kivitz, et al.. (2025). Efficacy and Safety of ABBV ‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial. Arthritis & Rheumatology. 77(12). 1673–1681.
4.
Tuttle, Jay, Edit Drescher, Jesus Abraham Simón Campos, et al.. (2023). POS0307 A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 82. 397–397. 1 indexed citations
5.
6.
Richette, Pascal, Ennio Lubrano, Edit Drescher, et al.. (2021). POS1030 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY BASELINE SKIN SEVERITY: A SUBGROUP ANALYSIS OF TWO PHASE III TRIALS. Annals of the Rheumatic Diseases. 80. 786–787. 1 indexed citations
7.
Strand, Vibeke, Filip Van den Bosch, Roberto Ranza, et al.. (2021). Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. Rheumatology and Therapy. 8(4). 1827–1844. 14 indexed citations
8.
Burmester, Gerd R, Edit Drescher, Paweł Hrycaj, et al.. (2020). Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis. Clinical Rheumatology. 39(11). 3341–3352. 13 indexed citations
9.
Yamanaka, Hisashi, Naoyuki Kamatani, Yoshiya Tanaka, et al.. (2019). AB0416 A COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF YLB113 AND ETANERCEPT REFERENCE PRODUCT FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 78. 1670–1670. 1 indexed citations
10.
11.
Genovese, Mark C., Désirée van der Heijde, Maxime Dougados, et al.. (2017). BARICITINIB INHIBITS RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS). Internal Medicine Journal. 47. 32–32. 1 indexed citations
12.
Heijde, Désirée van der, Atul Deodhar, James Cheng‐Chung Wei, et al.. (2017). Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Annals of the Rheumatic Diseases. 76(8). 1340–1347. 272 indexed citations breakdown →
13.
Dougados, Maxime, D. van der Heijde, Maria Greenwald, et al.. (2016). Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study. The Journal of Rheumatology. 43(6). 1188–1188. 2 indexed citations
14.
Dougados, Maxime, Désirée van der Heijde, Ying‐Chou Chen, et al.. (2016). Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases. 76(1). 88–95. 301 indexed citations breakdown →
15.
Heijde, Désirée van der, James Cheng‐Chung Wei, Edit Drescher, et al.. (2015). Tofacitinib in Patients with Ankylosing Spondylitis: A Phase 2, 16-Week, Randomized, Placebo-Controlled, Dose-Ranging Study. Arthritis & Rheumatism. 67. 3 indexed citations
16.
Dougados, Maxime, D. van der Heijde, Yu‐Chi Chen, et al.. (2015). LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study. Annals of the Rheumatic Diseases. 74. 79–79. 24 indexed citations
17.
Taylor, Peter C., Mark C. Genovese, Edward Keystone, et al.. (2013). 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Lara D. Veeken. 52. 44–45. 1 indexed citations
18.
Genovese, M. C., Ed Keystone, P. W. J. Taylor, et al.. (2012). 24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis.. Oxford University Research Archive (ORA) (University of Oxford). 64(10). 10 indexed citations
19.
Tak, Paul P., Andra Bălănescu, Vira Tseluyko, et al.. (2012). Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Annals of the Rheumatic Diseases. 72(3). 337–344. 76 indexed citations
20.
Drescher, Edit, et al.. (1988). Radiologische Diagnostik nach komplizierter distaler Radiusfraktur unter besonderer Berücksichtigung der Computertomographie. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 148(3). 295–300. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Šárka Forejtová Breakdown of academic impact, for papers by Joel Kremer Breakdown of academic impact, for papers by David Musselman Breakdown of academic impact, for papers by Charles Ludivico Breakdown of academic impact, for papers by Yvonne Sherrer Breakdown of academic impact, for papers by M. C. Genovese Breakdown of academic impact, for papers by J. Box Breakdown of academic impact, for papers by Eva Pérez‐Pampín Breakdown of academic impact, for papers by Alvina D. Chu Breakdown of academic impact, for papers by Artur Racewicz
Rankless by CCL
2026